September 3, 2024 03:36 PM EDTUpdated September 6, 11:33 PM

Court's ruling on Illumina-Grail deal could signal a limit to European antitrust powers

Jared Whitlock

Features Editor

Illumina’s legal victory against the European Union’s antitrust enforcer won’t give the testing company back its $7.1 billion merger with Grail. But it might dampen …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Court's ruling on Illumina-Grail deal could signal a limit to European antitrust powers

Jared Whitlock

Features Editor

Sign up to read this article for free.

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

Court's rul­ing on Il­lu­mi­na-Grail deal could sig­nal a lim­it to Eu­ro­pean an­titrust pow­ers

Jared Whitlock

Features Editor

Sign up to read this article for free.

more like this

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer but da­ta caveats damp­en ex­cite­ment

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Court's ruling on Illumina-Grail deal could signal a limit to European antitrust powers

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing